Systemic therapy with PDE4 inhibitors is associated with gastrointestinal adverse events (especially nausea), so topical therapy appears to be the optimal approach with respect to PDE4 inhibition in AD treatment 6, 7. This evidence concerns the gene PDE4A and Alzheimer disease.